These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37725855)

  • 1. DNA damage repair profiling of esophageal squamous cell carcinoma uncovers clinically relevant molecular subtypes with distinct prognoses and therapeutic vulnerabilities.
    Zhao N; Zhang Z; Wang Q; Li L; Wei Z; Chen H; Zhou M; Liu Z; Su J
    EBioMedicine; 2023 Oct; 96():104801. PubMed ID: 37725855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma.
    Gao W; Liu S; Wu Y; Wei W; Yang Q; Li W; Chen H; Luo A; Wang Y; Liu Z
    EBioMedicine; 2024 Jul; 105():105177. PubMed ID: 38924839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of altered DNA damage repair genes on mutational processes and immune cell infiltration in esophageal squamous cell carcinoma.
    Yuan H; Qing T; Zhu S; Yang X; Wu W; Xu K; Chen H; Jiang Y; Zhu C; Yuan Z; Zhang T; Jin L; Suo C; Lu M; Chen X; Ye W
    Cancer Med; 2023 Apr; 12(8):10077-10090. PubMed ID: 36708047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the DNA damage repair-associated signature.
    Zhang P; Wen B; Gong J; Liu Z; Zhang M; Zhou G; Zhang L; Zhang Z
    Environ Toxicol; 2024 May; 39(5):2803-2816. PubMed ID: 38287713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma.
    Guo JC; Lin CC; Hsu CL; Huang TC; Kuo HY; Lin CY; Lien MY; Cheng AL; Hsu CH
    Esophagus; 2022 Oct; 19(4):693-701. PubMed ID: 35816242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma.
    Meng X; Duan C; Pang H; Chen Q; Han B; Zha C; Dinislam M; Wu P; Li Z; Zhao S; Wang R; Lin L; Jiang C; Cai J
    EBioMedicine; 2019 Mar; 41():185-199. PubMed ID: 30773478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering Treg cell roles in esophageal squamous cell carcinoma: a comprehensive prognostic and immunotherapeutic analysis.
    Zhang P; Dong S; Sun W; Zhong W; Xiong J; Gong X; Li J; Lin H; Zhuang Y
    Front Mol Biosci; 2023; 10():1277530. PubMed ID: 37842637
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrative analysis of bulk and single-cell gene expression profiles to identify tumor-associated macrophage-derived CCL18 as a therapeutic target of esophageal squamous cell carcinoma.
    Sui X; Chen C; Zhou X; Wen X; Shi C; Chen G; Liu J; He Z; Yao Y; Li Y; Gao Y
    J Exp Clin Cancer Res; 2023 Feb; 42(1):51. PubMed ID: 36850011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Profiling of Lower-Grade Gliomas Subtype with Distinct Molecular and Clinicopathologic Characteristics via Altered DNA-Damage Repair Features.
    Maimaiti A; Liu Y; Abulaiti A; Wang X; Feng Z; Wang J; Mijiti M; Turhon M; Alimu N; Wang Y; Liang W; Jiang L; Pei Y
    J Mol Neurosci; 2023 May; 73(4-5):269-286. PubMed ID: 37067735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the immune modulation through deep transcriptomic profiling and therapeutic implications of DNA damage repair pattern in hepatocellular carcinoma.
    Hong W; Zhang Y; Wang S; Zheng D; Hsu S; Zhou J; Fan J; Zeng Z; Wang N; Ding Z; Yu M; Gao Q; Du S
    Cancer Lett; 2024 Feb; 582():216594. PubMed ID: 38135208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
    Chen G; Zhu YJ; Chen J; Miao F; Wu N; Song Y; Mao BB; Wang SZ; Xu F; Chen ZM
    Neoplasma; 2022 Dec; 69(6):1314-1321. PubMed ID: 36264776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prognostic Signature Based on Immunogenomic Profiling Offers Guidance for Esophageal Squamous Cell Cancer Treatment.
    Gao J; Tang T; Zhang B; Li G
    Front Oncol; 2021; 11():603634. PubMed ID: 33718151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy.
    Zheng Y; Gao Q; Su X; Xiao C; Yu B; Huang S; Sun Y; Wu S; Wo Y; Xu Q; Xu N; Yu H
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Niche Network-Defined Subtypes Predict Immunotherapy Response of Esophageal Squamous Cell Cancer.
    Ko KP; Zhang S; Huang Y; Kim B; Zou G; Jun S; Zhang J; Martin C; Dunbar KJ; Efe G; Rustgi AK; Zhang H; Nakagawa H; Park JI
    bioRxiv; 2023 Feb; ():. PubMed ID: 36824935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer.
    Yi L; Huang P; Zou X; Guo L; Gu Y; Wen C; Wu G
    Pharmacol Res; 2020 Nov; 161():105144. PubMed ID: 32810627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The identification of heterogeneous reactive oxygen subtypes in esophageal squamous cell carcinoma to aid patient prognosis and immunotherapy.
    Lu Q; Yang Q; Zhao J; Li G; Zhang J; Jia C; Wan Y; Chen Y
    Heliyon; 2024 Aug; 10(15):e35235. PubMed ID: 39165982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Potential of Exosome-Related LncRNA Pairs as Predictors for Immune Microenvironment, Survival Outcome, and Microbiotain Landscape in Esophageal Squamous Cell Carcinoma.
    Zhao F; Li Z; Dong Z; Wang Z; Guo P; Zhang D; Li S
    Front Immunol; 2022; 13():918154. PubMed ID: 35880180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-cancer landscape of T-cell exhaustion heterogeneity within the tumor microenvironment revealed a progressive roadmap of hierarchical dysfunction associated with prognosis and therapeutic efficacy.
    Zhang Z; Chen L; Chen H; Zhao J; Li K; Sun J; Zhou M
    EBioMedicine; 2022 Sep; 83():104207. PubMed ID: 35961204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling transcriptional heterogeneity of epithelium, fibroblasts, and immune cells in esophageal squamous cell carcinoma by single-cell RNA sequencing.
    Shi K; Li Y; Yang L; Zhang Z; Guo D; Zhang J; Lu Y
    FASEB J; 2022 Nov; 36(11):e22620. PubMed ID: 36260317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.